AS-IV has been demonstrated to improve cardiac function and decrease myocardial hypertrophy in several in vivo studies by decreasing oxidative stress and activating calpain-1, inhibiting the TBK1/PI3K/AKT signaling pathway, and several other additional mechanisms. The gene discussed is CAPN1; the disease is cardiac hypertrophy.